XY Capital Ltd Increases Holdings in Telix Pharmaceuticals Limited $TLX

XY Capital Ltd increased its position in Telix Pharmaceuticals Limited (NASDAQ:TLX) by 468.0% during the second quarter, HoldingsChannel.com reports. The fund owned 71,291 shares of the company’s stock after acquiring an additional 58,739 shares during the quarter. Telix Pharmaceuticals accounts for approximately 0.8% of XY Capital Ltd’s holdings, making the stock its 20th largest holding. XY Capital Ltd’s holdings in Telix Pharmaceuticals were worth $822,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hennion & Walsh Asset Management Inc. purchased a new stake in Telix Pharmaceuticals during the second quarter worth $1,731,000. Bank of America Corp DE grew its holdings in Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares during the last quarter. Lazard Asset Management LLC increased its position in shares of Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after buying an additional 39,400 shares in the last quarter. Private Advisor Group LLC increased its position in shares of Telix Pharmaceuticals by 276.3% in the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after buying an additional 128,070 shares in the last quarter. Finally, Vident Advisory LLC acquired a new position in shares of Telix Pharmaceuticals during the 4th quarter worth $204,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Wedbush restated an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Royal Bank Of Canada cut shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.40.

Telix Pharmaceuticals Trading Up 1.7%

Shares of TLX stock opened at $11.94 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16. The company has a 50 day moving average price of $11.21 and a 200 day moving average price of $9.96. Telix Pharmaceuticals Limited has a one year low of $6.28 and a one year high of $12.48.

Telix Pharmaceuticals Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.